Biostax (BTAX) 10-K 31 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2015	Jun. 30, 2014
Document And Entity Information
Entity Registrant Name	Immune Therapeutics, Inc.
Entity Central Index Key	1559356
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$20,876,858
Entity Common Stock, Shares Outstanding		144,553,198
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash and cash equivalents	$191,987	$406,596
Prepaids and Other Current assets	30,000	215,900
Total current assets	221,987	622,496
Fixed Assets:
Computer equipment, net of accumulated depreciation of $3,778 and $1,293 respectively	4,235	5,607
Intangible Assets:
Patents and licenses, net of amortization of $1,201,678 and $4,422,375, respectively	5,818,585	18,546,548
Deposits	10,183	17,435
Total assets	6,054,990	19,192,086
Current Liabilities:
Accounts payable	2,077,194	839,909
Payable to officer	0	76,000
Accrued liabilities	1,111,839	588,271
Current portion of patent liability	0	118,333
Current portion of notes payable	186,067	817,197
Total current liabilities	3,375,100	2,439,710
Non-current liabilities:
Notes payable related party	0	121,128
Notes payable, less current portion	327,458	0
Total non-current liabilities	327,458	121,128
Total liabilities	3,702,558	2,560,838
Commitments and Contingencies (Note 11)
Stockholders' Equity:
Common stock - par value $0.0001; 500,000,000 shares authorized; 134,417,210 and 74,161,639 shares issued and outstanding respectively	13,442	7,416
Additional paid in capital	337,985,787	308,180,119
Stock issuances due	847,279	4,893,499
Prepaid services	-3,553,185	-13,447,109
Accumulated deficit	-333,547,377	-283,002,677
Equity attributable to common shareholders	1,745,946	16,631,248
Non-controlling interest	606,487
Total stockholders' equity	2,352,432	16,631,247
Total liabilities and stockholders' equity	$6,054,990	$19,192,086

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accumulated depreciation	$3,778	$1,293
Amortization	$7,299,201	$4,422,375
Common Stock, Par Value	$0.00	$0.00
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares Issued	134,417,210	74,161,639
Common Stock, Shares Outstanding	134,417,210	74,161,639
Cytocom [Member]
Common Stock, Par Value	$0.00
Common Stock, Shares Authorized	400,000,000
Common Stock, Shares Issued	253,342,522
Common Stock, Shares Outstanding	0

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Revenues, net	$0	$0
Operating expenses:
Selling, general and administrative	4,072,277	5,337,348
Research and development expense	2,413,286	2,460,604
Stock issued for services general and administrative	19,116,075	55,235,667
Stock issued for services research and development	5,126,250	19,563,347
Warrant valuation general and administrative	1,748,576	10,531,073
Depreciation and amortization expense	2,879,311	2,853,436
Impairment of intangible assets	9,908,477	0
Total operating expenses	45,264,252	95,981,475
Loss from operations	-45,264,252	-95,981,475
Other expense:
Interest expense	-388,221	-1,437,392
Foreign Exchange loss	-783	-224
Loss on settlement of debt	-4,284,957	-8,640,971
Total other expense	-4,673,961	-10,078,587
Net loss	-49,938,213	-106,060,062
Net loss attributable to non-controlling interest	-1,684,996
Net loss attributable to common shareholders	($48,253,217)	($106,060,062)
Basic and diluted loss per share attributed to common shareholders:
Net Loss per share	($0.41)	($1.85)
Weighted average number of shares outstanding	98,508,458	57,234,251

Statements_of_Shockholders_Equ

Statements of Shockholders Equity (USD $)	Common Stock	Additional Paid-In Capital	Stock To Be Issued	Prepaid Services	Accumulated Deficit	Noncontrolling Interests	Total
Beginning Balance, Amount at Dec. 31, 2012	$4,549	$196,673,715	$3,690,960	($6,082,771)	($176,942,616)		$17,343,837
Beginning Balance, Shares at Dec. 31, 2012	45,489,368
Return of common stock for prepaid services, Shares	-350,000
Return of common stock for prepaid services, Amount	-35	-315					-350
Issuance of common stock for prepaid services, Shares	20,903,000						20,903,000
Issuance of common stock for prepaid services, Amount	2,090	82,161,260		-82,163,350
Amortization of prepaid services				74,799,012			74,799,012
Issuance of common stock in exchange for debt, Shares	1,567,103
Issuance of common stock in exchange for debt, Amount	157	7,456,642	1,252,000				1,455,561
Issuance of common stock for Jill Smith/LDN license, Shares	300,000
Issuance of common stock for Jill Smith/LDN license, Amount	30	2,714,970	-2,715,000				2,550,000
Issuance of common stock for Penn State License, Shares	300,000
Issuance of common stock for Penn State License, Amount	300	2,549,970					750,000
Issuance of common stock issued for charitable donation, Shares	100,000
Issuance of common stock issued for charitable donation, Amount	100	749,990					8,708,799
Issuance of common stock for loan expenses and interest, Shares	387,500						387,500
Issuance of common stock for loan expenses and interest, Amount	39	1,230,722	224,800				6,553,377
Issuance of common stock for cash and exercise of warrants, Shares	5,464,668
Issuance of common stock for cash and exercise of warrants, Amount	546	4,112,092	2,440,739				10,531,073
Net loss					-106,060,062		-106,060,062
Ending Balance, Amount at Dec. 31, 2013	7,416	308,180,119	4,893,499	-13,447,109	-283,002,678		16,631,247
Ending Balance, Shares at Dec. 31, 2013	74,161,639
Issuance of common stock for prepaid services, Shares	17,178,294						17,178,294
Issuance of common stock for prepaid services, Amount	1,718	11,275,282	787,501	-12,962,001			-897,500
Return of common stock for charitable donation, Shares	-100,000
Return of common stock for charitable donation, Amount	-10	-749,990					-750,000
Amortization of prepaid services				22,855,925			22,855,925
Issuance of common stock for patents and licenses, Shares	1,600,000
Issuance of common stock for patents and licenses, Amount	160	467,840					468,000
Issuance of common stock for legal settlement, Shares	650,000
Issuance of common stock for legal settlement, Amount	65	448,435					448,500
Issuance of common stock to employees and consultants, Shares	6,329,000
Issuance of common stock to employees and consultants, Amount	633	3,176,424	-1,028,157				2,148,900
Issuance of common stock in exchange for debt, Shares	24,037,450
Issuance of common stock in exchange for debt, Amount	2,404	8,250,396	-1,150,000				7,102,800
Issuance of common stock for loan expenses and interest, Shares	670,000						670,000
Issuance of common stock for loan expenses and interest, Amount	67	527,183	-224,800				302,450
Issuance of common stock for cash and exercise of warrants, Shares	9,890,827
Issuance of common stock for cash and exercise of warrants, Amount	989	4,661,522	-2,430,764				2,231,747
Issuance and modification of common stock warrants, Amount		1,748,576					1,748,576
Non-controlling interest in Cytocom, Inc. (Note 2)					-2,291,483	2,291,483
Net loss					-48,253,217	-1,684,996	-49,938,213
Ending Balance, Amount at Dec. 31, 2014	$13,442	$337,985,787	$847,279	($3,553,185)	($333,547,338)	$606,487	$2,352,432
Ending Balance, Shares at Dec. 31, 2014	134,417,210

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss including non-controlling interest	($49,938,213)	($106,060,062)
Adjustments to reconcile loss to net cash flows used in operating activities:
Depreciation	2,485	1,175
Amortization	2,876,826	2,852,261
Stock issued for services	1,251,401	0
Stock issued for legal settlement	448,500	0
Stock issued for patents and license fees	468,000	0
Amortization of stock issued for prepaid services	22,891,924	74,798,662
Impairment of intangible assets	9,908,477	0
Debt discount	25,000	0
Loss on settlement of debt and accounts payable	4,248,957	8,594,633
Stock warrant expense	1,748,576	10,531,073
Stock Issued for donation	-750,000	750,000
Stock issued for loan expenses and interest	302,450	1,455,561
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	246,342	-208,407
Accrued liabilities	630,662	161,061
Accounts payable	1,795,518	553,211
Net cash used in operating activities	-3,843,095	-6,570,832
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of Penn State License	-57,340	-160,539
Purchase of computer equipment	-1,113	-5,838
Net cash used in investing activities	-58,453	-166,377
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of common stock	2,231,747	6,553,377
Proceeds from notes payable	1,623,525	599,000
Payments made on patent liability	-118,333	-221,667
Repayment of notes payable	0	-100,000
Repayment of notes payable to related party	-50,000	0
Net cash provided by financing activities	3,686,939	6,830,710
Increase (decrease) in cash	-214,609	93,501
Cash and cash equivalents, beginning of year	406,596	313,095
Cash and cash equivalents, end of year	191,987	406,596
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	4,538
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Accrued liabilities for purchase of Smith LDN patent		2,715,000
Conversion of debt and accrued interest to common stock	2,159,248	114,166
Common shares issued for Penn State license		2,550,000
Non-controlling interest	2,105,062
Stock dividend
Shares issued for accounts payable and accrued interest	$580,404

1_Organization_and_Description

1. Organization and Description of Business	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
1. Organization and Description of Business	Immune Therapeutics, Inc. (the “Company”) was initially incorporated in Florida on December 2, 1993 as Resort Clubs International, Inc. (“Resort Clubs”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on May 27, 1998 and began trading in November 1999 through the filing of a 15C-211. On November 10, 2004, Galliano merged with Resort Clubs.  Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (“pH Environmental”).
	On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all of the outstanding shares of TNI BioTech IP, Inc. On September 4, 2014, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc.   We filed our name change amendment with the Secretary of State of Florida on October 27, 2014 changing our name to Immune Therapeutics, Inc.
	The Company currently resides in Orlando, Florida. In July 2012, the Company’s focus turned to acquiring patents that would protect and advance the development of new uses of opioid-related immune- therapies, such as low dose naltrexone (“LDN”) and Methionine [Met5]-enkephalin (“MENK”). The Company’s therapies are believed to stimulate and/or regulate the immune system in such a way that they provide the potential to treat a variety of diseases.  We believe our therapies may be able to correct abnormalities or deficiencies in the immune system in diseases such as HIV infection, autoimmune disease, immune disorders, or cancer; all of which can lead to disease progression and life-threatening situations when the immune system is not functioning optimally.
	In October 2012, the Company formed TNI BioTech International, Ltd., a BVI company in Tortola, British Virgin Islands, which was set up to allow the Company to market and sell LDN in those countries outside the U.S. in which we have been able to obtain approval to sell the Company’s products.
	In August 2013, the Company formed its United Kingdom subsidiary, TNI BioTech, LTD (the “UK Subsidiary”). The UK Subsidiary received approval to be considered a micro, small or medium-sized enterprise (“SME”) with the European Medicines Agency (“EMA”) on August 21, 2013. The designation provides the UK Subsidiary with significant discounts when holding meetings or submitting filings to the EMA. On September 19, 2013, the UK Subsidiary submitted a pre-submission package to the EMA regarding Crohn’s Disease. The EMA granted the UK Subsidiary a meeting that took place on September 27, 2013. The UK Subsidiary is eligible to benefit from the provisions for administrative and financial assistance for SMEs set out in Regulation (EC) No 2049/2005.
	In December 2013, the Company formed a new subsidiary, Cytocom Inc., to focus on conducting LDN and MENK clinical trials in the United States. In December 2014, the Company completed the distribution of common stock of Cytocom Inc. to its shareholders. As part of the transaction, the Company retained exclusive rights to all international patents, in-country approvals, formulations, trademarks, manufacturing, marketing, sales, and distributions rights in emerging nations, including Africa, Central America, South America, Russia, India, China, Far East, and The Commonwealth of Independent States (former Soviet Union).  The Company will continue to have access to existing clinical data as well as any new data generated by Cytocom Inc. during drug development.  On December 8, 2014, the number of Cytocom Inc. shares of common stock that were issued to our shareholders totaled 113,242,522 shares.   In connection with the transaction, Cytocom Inc. issued 140,100,000 shares of its common stock to the Company, which has allowed the Company to retain a 55% stake in Cytocom Inc. until such time as funding for Cytocom Inc. closes.
	In March 2014, the Company incorporated Airmed Biopharma Limited, an Irish corporation with an address in Dublin, Ireland, and Airmed Holdings Limited, an Irish company domiciled in Bermuda. The Irish companies were set up to benefit from incentives granted by the Irish government for the establishment of pharmaceutical companies (many of the world’s leading pharmaceutical companies have located in Ireland), and so that the Company could take advantage of Ireland's status as a member of the European Union and the European Economic Area.  An Irish limited liability company enjoys a low corporate income tax rate of 12.5%, one of the lowest in the world. The Irish-domiciled company hopes to qualify for tax incentives for Irish holding/headquartered companies and to benefit from the network of double tax treaties that reduce withholding taxes.  TNI BioTech International, Ltd. will manage our international distribution, using product that is manufactured in Ireland and elsewhere.
	We are focused on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases and immune disorders by combating these severe and fatal diseases through the stimulation and/or regulation of the body’s immune system. Our growth strategy includes the near-term commercialization of our existing immunotherapies targeting cancer, Crohn’s disease and/or HIV/AIDS.
	The Company is currently a party to agreements to lease office space in White Plains, New York and Orlando, Florida. The White Plains office is no longer in use.
	Going Concern
	The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through private equity financings. Management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidate and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings, and may seek additional capital through arrangements with strategic partners or from other sources. Based on the Company’s operating plan, existing working capital at December 31, 2014 was not sufficient to meet the cash requirements to fund planned operations through December 31, 2015 without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.
	The Company has experienced a net loss from operations of $49,938,213 and has used cash and cash equivalents for operations in the amount of $3,843,095 during the year ended December 31, 2014, resulting in stockholder’s equity of $2,352,432.

2_Summary_of_Significant_Accou

2. Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
2. Summary of Significant Accounting Policies	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with United States (U.S.) generally accepted accounting principles (U.S. GAAP) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented.
	The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2014. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.
	Use of Estimates
	The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.
	Cash, Cash Equivalents, and Short-Term Investments
	The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At December 31, 2014, the Company has no uninsured cash balances.
	Segment and Geographic Information
	Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.
	Fair Value of Financial Instruments
	In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments” , the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments.  Cash,  accounts payable, payable to officer, patent liability and net liabilities of discontinued operations are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments.   The carrying value of notes payable and notes payable related party also approximate fair value since they bear market rates of interest and other terms.  None of these instruments are held for trading purposes.
	Fair Value Measurements
	The ASC Topic 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in accordance with U.S. generally accepted accounting principles, and requires certain disclosures about fair value measurements. In general, fair values of financial instruments are based upon quoted market prices, where available. If such quoted market prices are not available, fair value is based upon internally developed models that primarily use, as inputs, observable market-based parameters. Valuation adjustments may be made to ensure that financial instruments are recorded at fair value. These adjustments may include amounts to reflect counterparty credit quality and the customer's creditworthiness, among other things, as well as unobservable parameters. Any such valuation adjustments are applied consistently over time.
	Property and Equipment
	Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense from continuing operations for the years ended December 31, 2014 and December 31, 2013 was $2,485 and $1,175, respectively.
	Intangible Assets
	Costs incurred to acquire and/or develop the Company’s product licenses and patents are capitalized and amortized by straight-line methods over estimated useful lives of seven to sixteen years. Intangible assets are stated at the lower of cost or estimated fair market value.  During the years ended December 31, 2014 and December 31, 2013, the Company capitalized $57,340 and $2,710,539 respectively, of such costs incurred for the Company’s acquisition of licenses for the patents. (See Note 10).  Amortization expense for the years ended December 31, 2014 and December 31, 2013 was $2,876,826 and $2,852,261, respectively.
	Impairment of Long-Lived Assets
	The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “Property, Plant and Equipment.” If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value. In 2014, the Company determined that the carrying amount recoded for the acquisition of licenses and patents related to MENK were impaired, and recorded an impairment loss of $9,908,477. No impairment losses were recognized for the year ended December 31, 2013.
	Research and Development Costs
	Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.
	Income Taxes
	The Company follows FASB ASC Topic 740, “Income Taxes” , which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
	The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of December 31, 2014, and 2013, the Company does not have a liability for unrecognized tax uncertainties.
	The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of December 31, 2014, and 2013, the Company has not accrued any interest or penalties related to uncertain tax positions.
	Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration
	The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair market value of the Company’s common stock at the date of the agreement.
	The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “Equity-Based Payments to Non-Employees.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.
	Non-controlling Interest
	In accordance with ASC 810, Consolidation, the Company consolidates Cytocom, Inc. The non-controlling interests in Cytocom represent the interests of outside shareholders in the equity and results of operations of Cytocom.
	The Company has adopted changes issued by the Financial Accounting Standards Board (“FASB”) to the accounting for non-controlling interests in consolidated financial statements. These changes require, among other items, that a non-controlling interest be included within equity separate from the parent’s equity; consolidated net income be reported at amounts inclusive of both the parent’s and non-controlling interest’s shares; and, separately, the amounts of consolidated net income attributable to the parent and non-controlling interest all be reported on the consolidated statements of operations and comprehensive loss.
	Net Loss per Share
	Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.
	Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common equivalent shares):
		Year Ended December 31,
		2014		2013
	Common Stock Purchase Warrants		9,296,750		7,957,500
	Recent Accounting Standards
	During the year ended December 31, 2014 and through March 31, 2015, there were several new accounting pronouncements issued by the Financial Accounting Standards Board.  Each of these pronouncements, as applicable, has been or will be adopted by the Company.  Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.
	The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2014, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

3_Property_and_Equipment

3. Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
3. Property and Equipment		December 31,
		2014			2013
	Property and equipment:
	Computer equipment	$	8,013		$	6,900
	Less accumulated depreciation		(3,778	)		(1,293	)
	Property and equipment, net	$	4,235		$	5,607
	The Company utilizes the straight-line method for depreciation, using three to five-year depreciable asset lives. Depreciation expense was not material for all periods presented.

4_Accrued_Liabilities

4. Accrued Liabilities	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
4. Accrued Liabilities	Accrued expenses and other liabilities consist of the following:
		December 31,
		2014		2013
	Retainer for legal services	$	60,000	$	-
	Accrued payroll to officers and others		762,633		548,291
	Accrued interest - notes payable		1,808		39,980
	Estimated legal settlement		278,681		-
	Other accrued liabilities		6,933		-
	State payroll taxes		1,784		-
	Total accrued expenses and other liabilities	$	1,111,839	$	588,271

5_Notes_Payable

5. Notes Payable	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
5. Notes Payable	At December 31, 2013, the Company had promissory notes outstanding totaling $817,197.  At June 30, 2014, the Company had promissory notes outstanding totaling $1,442,197.  At June 30, 2014, those promissory notes had maturity dates ranging between September 2007 and July 2014.  The notes bore interest at rates between two and six percent per annum.  As of June 30, 2014, the Company had accrued $67,863 in unpaid interest on those notes.
	During the three months ended September 30, 2014, the Company settled all of the notes that had been outstanding at June 30, 2014, together with accrued interest owing on the notes, by issuing 20,731,601 shares, at a range of $0.10 to $0.25 per share, as repayment of principal and interest. The Company recognized a loss of $4,022,957 on the settlement of these notes.
	Between July 1, 2014 and December 31, 2014, the Company issued additional promissory notes totaling $513,525.  At December 31, 2014, the following promissory notes were outstanding:
	●	Promissory note issued July 29, 2014 to Ira Gaines.  The balance outstanding as of December 31, 2014 and 2013 was $100,000 and $0, respectively. The note matures on January 27, 2015 and earns interest at a rate of 18% per annum.
	●	Promissory notes issued between November 26, 2014 and December 31, 2014, to raise up to $2,000,000 in debt.  The balance outstanding as of December 31, 2014 and 2013 was $406,525 and $0, respectively. In accordance with the loan agreements for this debt, each lender will earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity.  Each lender will be repaid in 36 monthly installments of principal and interest commencing June 15, 2015.
	●	Promissory note issued October 17, 2014 to Roger Bozarth.  The balance outstanding as of December 31, 2014 and 2013 was $7,000 and $0, respectively.  The note matures on October 17, 2015 and earns interest at a rate of 2% per annum.
	As of December 31, 2014, the Company had accrued $1,808 in unpaid interest. During 2014, the Company issued 670,000 shares with a fair value of $302,450 (compared to 387,500 shares with a fair value $1,230,761 in 2013) for origination fees and loan expenses under promissory notes.

6_Capital_StructureCommon_Stoc

6. Capital Structure-Common Stock and Common Stock Purchase Warrants	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
6. Capital Structure-Common Stock and Common Stock Purchase Warrants	Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend.
	As of December 31, 2014 and 2013, the Company was authorized to issue 500,000,000 common shares at a par value of $0.0001 per share. The par value at December 31, 2013 was reported at $0.001 per share. The financial statements at December 31, 2013 have been reclassified to reflect a par value of $0.0001, which resulted in a decrease in common stock of $66,744 and an increase in additional paid-in capital in the same amount.
	On March 18, 2013, the Company affected a 1 for 1,000 reverse stock split of the Company’s Common Stock, resulting in a reduction of the number of shares outstanding of the Company from approximately 113,644,000 to approximately 113,644.  Persons holding less than 1,000 shares of Common Stock received one share of Common Stock.  The rights and privileges of the holders of shares of Common Stock were substantially unaffected by the reverse stock split. All issued and outstanding options, warrants and convertible securities were appropriately adjusted for the reverse stock split automatically on the effective date of the reverse stock split, and have been presented in the financial statements to adjust for the reverse stock split.
	As of December 31, 2014, the Company had 134,417,210 shares of common stock outstanding and 74,161,639 outstanding as of December 31, 2013.
	Stock Warrants
	In 2014, the Company issued 2,358,000 warrants, exercisable into one share of common stock of the Company for each warrant at prices between $0.14 and $1.50 per share.  The warrants expire between January 2016 and December 2019.
	The warrants were issued as an additional incentive to purchase our common stock.  Accordingly, an expense was recognized based upon the estimated fair value of the warrants using the Black-Scholes pricing model.  The variables used in the Black-Scholes pricing model during the year ended December 31, 2014 were a weighted average exercise price of $0.69, a discount rate of 90%, an expected life of 5 years, and volatility of 163%. Fair value of $1,748,576 was calculated using the Black-Scholes Model.
	During 2014, there were no modifications of the terms of any warrants issued by the Company.  In 2013,  the Company agreed to modify the terms of certain warrants, as follows:
	●	The exercise price of 32 warrants was reduced from a range of $1.00 to $15.00 to a range of $0.50 to $0.75.
	●	The reduction in exercise price applied to 15 shareholders, and affected 4,461,668 shares of common stock.
	●	The total incremental compensation cost resulting from the modifications was $8,334,493.
	Following is a summary of outstanding stock warrants at December 31, 2014 and 2013 and activity during the years then ended:
			Number of Shares		Exercise Price		Weighted Average Price
	Warrants as of December 31, 2013			7,957,500	$	1.00 – 15.00	$	1.77
	Issued in 2014			2,358,000	$	0.14-1.50	$	1.08
	Expired			-	$	-	$	-
	Exercised			-918,750	$	0.5	$	0.5
	Warrants as of December 31, 2014			9,396,750	$	0.14-15	$	1.72
	Summary of outstanding warrants as of December 31, 2014:
	Expiration Date		Number of Shares		Exercise Price		Remaining Life (years)
	Third Quarter 2015			407,500	$	1.50-2.00		0.75
	Fourth Quarter 2015			268,750	$	1.5		1
	Second Quarter 2016			37,500	$	3.00-5.00		1.5
	Third Quarter 2016			525,000	$	0.50-5.00		1.75
	Third Quarter 2017			1,500.00	$	1.00-1.50		2.75
	Fourth Quarter 2017			2,941,666	$	1.00-9.00		3
	First Quarter 2018			127,500	$	15		3.25
	Second Quarter 2018			33,334	$	15		3.5
	Third Quarter 2018			400,000	$	1.00-1.50		3.75
	Fourth Quarter 2018			1,197,500	$	1.00-1.50		4
	First Quarter 2019			1,048,000	$	1.5		4.25
	Third Quarter 2019			500,000	$	0.5		4.75
	Fourth Quarter 2019			410,000	$	0.14-1.50		5

7_Stock_Compensation

7. Stock Compensation	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
7. Stock Compensation	Shares Issued for Services
	During the years ended December 31, 2014 and 2013, the Company issued common stock of 17,178,294 and 20,903,000 respectively for consulting fees.  The Company valued these shares based upon the fair market value of the common stock at the dates of the agreements.  The consulting fees are amortized over the contract periods which are typically between 12 and 24 months.   The amortization of prepaid services totaled $21,959,925and $74,799,012 for the years ended December 31, 2014 and 2013.

8_Income_Taxes_Results_of_Oper

8. Income Taxes - Results of Operations	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
8. Income Taxes - Results of Operations	There was no income tax expense reflected in the results of operations for the years ended December 31, 2014 and 2013 because the Company incurred a net loss in both years.
	Deferred tax assets reflect the net income tax effect of temporary differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income taxes.
	Deferred tax assets:
		2014			2013
	Net operating losses	$	47,992,000		$	35,160,000
	Stock based compensation		29,020,000			29,019,000
	Amortization and depreciation		1,950,000			970,000
	Capitalization of start-up costs for tax purposes		254,000			1,854,000
	Loss on debt conversion  of debt		4,395,000			2,938,000
	Total deferred tax assets		86,915,000			69,941,000
	Valuation allowance		(86,915,000)			(69,941,000	)
	Total deferred tax assets, net	$	-		$	-
	The Company has recognized no tax benefit for the losses generated for the periods through December 31, 2013. ASC Topic 740 requires that a valuation allowance be provided if it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company’s ability to realize the benefit of its deferred tax asset will depend on the generation of future taxable income. Because the Company has yet to recognize revenue, we believe that the full valuation allowance should be provided.
	Our effective tax rate for fiscal years 2014 and 2013 was 0%. Our tax rate can be affected by recurring items, such as tax rates in foreign jurisdictions and the relative amount of income we earn in jurisdictions. It may also be affected by discrete items that may occur in any given year, but are not consistent from year to year.
	As of December 31, 2014, we have estimated federal and state income tax net operating loss (“NOL”) carry-forwards of approximately $1,500,000, which will expire in 2032-2036.
		2014						2013
		Amount			Percent			Amount			Percent
	Benefits for income tax at federal statutory rate	$	16,978,000			34%		$	36,060,000			34	%
	Change in valuation allowance		(16,973,000	)		-34%		$	(36,056,000	)		(34	)
	Permanent differences		(5,000	)		-			(4,000	)		-
	Non-deductible impairment of goodwill		-			-			-			-
		$	-			-		$	-			-	%

9_Subsequent_Events

9. Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
9. Subsequent Events	Between January 1, 2015 and March 31, 2015, the Company issued shares as follows:
		Number of Shares
	Issuance of common stock to employees and consultants	8,272,502
	Issuance of common stock for cash	264,000
	Issuance of common stock in exchange for debt	1,600,000
	As of March 31, 2015, the Company had outstanding 144,553,198 shares of common stock.

10_Lincenses_and_Supply_Agreem

10. Lincenses and Supply Agreements	12 Months Ended
	Dec. 31, 2014
Notes to Financial Statements
10. Lincenses and Supply Agreements	Patent and Subsidiary Acquisition
	The Company entered into a share exchange agreement on April 24, 2012 to acquire all of the outstanding shares of TNI BioTech IP, Inc. (“TNI IP”), a biotechnology firm incorporated in Florida and formed to acquire patents related to the treatment of cancer and HIV/AIDS and autoimmune diseases, using Met-enkephalin (“MENK”) and Naltraxone (“LDN”). The goal of TNI IP’s management was to enable mankind and civilization to combat fatal diseases by activating and mobilizing the body’s own immune system using TNI IP’s patented use of MENK.  The first patents acquired by TNI IP were acquired from Dr. Nicholas P. Plotnikoff and Professor Fengping Shan in 2012.  TNI IP was acquired in exchange for 20,250,000 shares of the Company’s common stock, of which 8,000,000 shares were issued to Dr. Plotnikoff for the acquisition of patents and the remaining 12,250,000 shares were issued to the founders of TNI IP in exchange for all of their right, title and interest in their TNI IP shares. The goodwill arising on the acquisition of TNI BioTech IP, Inc. was valued at $98,000,000 and license agreements arising from the acquisition of TNI IP were valued at $16,006,000.
	In connection with the share exchange, we entered into a Sale of Technology Agreement with Dr. Nicholas P. Plotnikoff on March 4, 2012, wherein Dr. Plotnikoff agreed to transfer and assign all of his rights, title and interest in: European Patent United Kingdom, Germany, France, Ireland EP 1401471 BI Methods for inducing sustained immune response; Russian Patent Russian Federation patent number 2313364; The Patent Office of the People’s Republic of China, Application No.: 200810165784.8 China Patent CN1015113407 A The Patent Office of the People’s Republic of China ISSN: 1006-2858 CN 21-1349/R; Patent Agencies Government of India Patent, Application number 1627/KOLNP/2003 number 220265 an Enkephalin Peptide Composition; and the US Patent Pending, US Patent Application 10/146.999 e. The Company received all the production formulations and technology designs from Dr. Plotnikoff necessary for the manufacturing, formulation, production and protocols of the MENK treatment of cancer and HIV/AIDS. As consideration for entering into the Sale of Technology Agreement, Dr. Plotnikoff received 8,000,000 shares of common stock, a royalty of a single-digit percentage on all sales of MENK and was granted the position of Non-Executive Chairman of the Board of Directors.
	At the time of the acquisition, the valuation of goodwill and other intangible assets were determined using the fair market price for the Company’s common stock, which were exchanged for shares of TNI IP.  In the fourth quarter of 2012, the Company performed an annual valuation to determine whether any goodwill or intangible assets that had been acquired by the Company were impaired. The result of this valuation was that material impairments were identified. The Company recognized an impairment of the goodwill arising on the acquisition of TNI IP of $98,000,000.
	Patent License Agreements
	On August 13, 2012, the Company signed an exclusive License Agreement with Ms. Jacqueline Young (the “Young Agreement”) for the intellectual property developed by Dr. Bernard Bihari relating to treatments with opioid antagonists such as naltrexone and Met-enkephalin for a variety of diseases and conditions including malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, chronic herpes virus infections, chronic herpes viral infections such as chronic genital herpes caused by the herpes simplex virus Type 2 and chronic infections due to the Epstein-Barr virus and a treatment method for humans infected with HTLV-III (AIDS) virus, including patients clinically diagnosed as suffering from AIDS and those suffering from AIDS-related complex (ARC).  The Bihari patents were acquired in exchange for 540,000 shares of the Company’s common stock with a fair market value of $972,000 and assumed liabilities of $400,000, which is payable to Ms. Young over a twenty-four month period in equal installments to reimburse her for the costs of a New York City office in accordance with the Young Agreement.  The patent liability at December 31, 2013 totaled $118,333. The cost of the patent totaled $1,372,000.  Additionally, the Company will pay the licensor a royalty payment of 1% of gross MENK sales and provide the licensor a position as non-executive chairman of the Company. The Young Agreement is valid for the life of the patents and expires on a country by country basis in each country where patent rights exist, upon the expiration of the last to expire patent in each country or in the event the patent in such country is held to be invalid and/or unenforceable (by a court or government body of competent jurisdiction) or admitted to be invalid or unenforceable. Additionally, we can cancel the Young Agreement upon 120 days’ written notice and shall pay all royalties and fees that have accrued under the Young Agreement. We have the exclusive rights to the intellectual property; however, Ms. Young retains a right to practice the patents licensed under the Young Agreement solely for noncommercial, academic research purposes.
	On December 24, 2012, the Company signed an agreement for the acquisition of patent rights (the “Smith Agreement”) for the intellectual property of Dr. Jill Smith and LDN Research Group, LLC (collectively, the “Licensor Parties”), whose members are Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Moshe Rogosnitzky and orphan drug designation by the FDA to a novel late-stage drug, trademarked “LDN,” for the treatment of Pediatric Crohn’s disease. The patent covers methods and formulations for treatment of the inflammatory and ulcerative diseases of the bowel, using naltrexone in low doses as an opioid antagonist. These patents were acquired in exchange for 300,000 shares of our common stock with a fair market value of $2,715,000 and payment of $165,384 (consisting of a $100,000 initial license fee and payment of $65,384 of expenses), which totaled $2,880,384.
	The Smith Agreement requires the Company to (i) use commercially reasonable efforts to develop, commercialize, market and sell licensed products in a manner consistent with a business plan, (ii) expend a minimum amount of funds per annum to develop and commercialize licensed products as soon as practicable, (iii) obtain all requisite regulatory approvals needed to use or sell licensed products in the field of use, and (iv) make the first commercial sale of a licensed product by March of 2017.
	The Company is required to pay an annual license fee, an annual running royalty on net sales of each licensed product or a minimum royalty, whichever is greater, and a sublicense fee on payments received by the Company from sublicensees. The Company has an exclusive, worldwide license to make, have made, use, lease, import, offer for sale and sell licensed products and to use the method under the patent rights. The Smith Agreement will terminate on the expiration or abandonment of the last patent to expire or ten years after the sale of the first licensed product. The Company may terminate the Smith Agreement upon 90 days’ written notice, provided all sublicenses are terminated and all amounts due and owing are paid to the Licensor Parties. The Licensor Parties may terminate the agreement ten days' after notice to the Company if the Company is ten days late in payment or there is a breach that remains uncured for ten days after written notice of such breach.
	The Company is also required to pay milestone payments after substantial achievement of certain milestone events for each licensed product including payment: upon initiation of each Phase III trial; upon positive completion of each Phase III clinical trial of the therapeutic use of an LDN compound in the field of use; when a New Drug Application (“NDA”) is accepted for review by the FDA; and when FDA approval to market the NDA is approved. The Company will issue shares upon reaching certain milestones including upon the first dosing of the first patient in a Phase III clinical trial for each licensed product, upon the first sale of each licensed product, and upon the achievement of a set dollar amount in cumulative sales for each licensed product covered by NDAs.
	As part of the Smith Agreement, the Company has the right to apply to the FDA for the transfer of the orphan drug status for the use of naltrexone for the treatment of pediatric Crohn’s disease and ulcerative colitis, the Investigation New Drug Application (“IND”), and the right to acquire the relevant clinical data set from Dr. Jill Smith.  Dr. Jill Smith made arrangements to transfer the IND to the Company as well as the relevant clinical data set, and the FDA has acknowledged that the Company is now the sponsor for this IND.
	On September 24, 2014, the Company and the Licensor Parties jointly agreed to terminate the Smith Agreement, and in place thereof, have the Licensor Parties grant a similar license in their patent rights to Cytocom Inc. pursuant to a Patent License Agreement between the Licensor Parties, Cytocom Inc. and the Company with substantially similar terms as set forth in the Smith Agreement.  Pursuant to this agreement, the Company issued 1,000,000 shares of its common stock valued at $270,000, upon execution to the Licensor Parties and the Company guaranteed the obligations of Cytocom Inc. to the Licensor Parties under the agreement.
	On January 18, 2013, the Company signed an exclusive licensing agreement with The Penn State Research Foundation to license all of the intellectual property developed by Dr. Ian S. Zagon, Dr. Patricia J. McLaughlin and Dr. Jill P. Smith for the treatment of cancer titled “Opioid Growth Factor and Cancer” and “Combination Therapy with Opioid Growth Factor and Taxanes for the Treatment of Cancer” (the “Foundation Agreement”).
	The Foundation Agreement requires the Company to: (a) use commercially reasonable efforts to develop, commercialize, market and sell licensed products in a manner consistent with a business plan; (b) expend a minimum amount of funds per annum to develop and commercialize licensed products as soon as practicable; (c) obtain all requisite regulatory approvals needed to use or sell licensed products in the field of use; and (d) make the first commercial sale of a licensed product by December 31, 2016.
	The Foundation Agreement provides that the Company must pay to the licensor an initial license fee, a license maintenance fee on each anniversary of the effective date of the Foundation Agreement, and an annual running royalty on net sales for each licensed product or a minimum royalty, whichever is greater.  In addition, the Company must pay a sublicense fee on payments received by the Company from sublicensees.
	The Foundation Agreement also requires the Company to make payments upon the achievement of certain milestone events including: initiation of each Phase II trial; initiation of each Phase III trial; when the NDA is accepted for review by the FDA; and when FDA approval to market is approved.  The Company must also issue shares upon certain milestones including upon the first dosing of the first patient in a Phase II clinical trial for each licensed product, upon the first dosing of the first patient in a Phase III clinical trial for each licensed product, upon the first sale of each licensed product, and upon the achievement of a set dollar amount of cumulative sales for each licensed product covered by NDAs.
	The Foundation Agreement terminates on the expiration or abandonment of the last patent to expire or become abandoned. The Company may terminate the Foundation Agreement at any time upon 60 days’ prior written notice and ceasing to make and sell all licensed products, the termination of all sublicenses and payment of all monies owed under the Foundation Agreement. The licensor may terminate the agreement 30 days after notice to the Company if the Company is 30 days late in payment or a breach that remains uncured for 45 days after written notice of such breach.
	In May of 2013, the Company executed a Patent License Agreement with Professor Fengping Shan (the “Shan Agreement”) pursuant to which it obtained exclusive rights to develop and commercialize the licensed technology. The licensed technology is the intellectual property developed and owned by Professor Shan (i) relating to the treatment of a variety of diseases and conditions with MENK including multiple forms of lymphoma and cancer and (ii) a treatment method for humans infected with the HLTV-III (AIDS) virus including AIDS and AIDS related complex (ARC). The licensed technology includes the methods and formulations for these treatments including all INDs, communications with regulatory agencies, patient data, and letters relating to these treatments. The licensed technology also includes certain patents developed by Professor Shan. Under the Shan Agreement, the Company must issue 500,000 shares to Professor Shan upon final transfer of the licenses, and reimburse Professor Shan for all out of pocket expenses in connection with the patents. The Company will pay Professor Shan a running royalty on gross sales subject to decreases if third party intellectual property is needed to complete such sale or product. The Shan Agreement lasts for the duration of each of the licensed patents however the Company may terminate the Shan Agreement on 120 days' written notice to Professor Shan.
	On August 6, 2014, Professor Fengping Shan executed an Assignment pursuant to which he transferred to the Company his entire right, title and interest in and to the licensed patents under the Shan Agreement and CN 201210302259 Application of combination of low-dose naltrexone and methionine-enkephalin to preparation of anti-cancer drug for the consideration of 500,000 shares of common stock valued at $140,000.

11_Commitments_and_Contingenci

11. Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
11. Commitments and Contingencies	Malawi Treatment Facilities
	On July 14, 2012, GB Oncology and Imaging Group LTD (“GBOIG”) in partnership with the Company signed a letter of intent agreement to collaborate with the Government of Malawi to assist in expanding the treatment of cancer, HIV/AIDS and other infectious diseases.
	The Company and GB will work in connection with the government of Malawi to open and operate clinics that provide treatments for HIV/AIDS, cancer and other infectious diseases. GBOIG and the Company expect to have the oncology and infectious disease clinic fully operational within 12 months of the signing of the agreement, and hope to begin treatment for HIV patients within 180 days. Under the letter of intent, the Company and GBOIG will begin by providing HIV/AIDS treatment to 25,000 patients and hopefully expanding to 500,000 within 24 months.  The Company shall contribute $1,000 in initial capital to the venture.  The Company shall be allocated 50% of the net income from the venture.  Either party may terminate the venture with 180 days’ notice to the other party prior to the one-year anniversary of the Agreement.  After the one-year anniversary, the agreement may only be terminated with 180 days' notice to the other party if the other party has breached the Agreement.
	GBOIG, a subsidiary of GB Energie LLC, is a Washington D.C. based minority woman-owned business managed by Dr. Gloria B. Herndon. Dr. Herndon is a former director of the Company.  Dr. Herndon’s directorship with the Company ended September 4, 2014.
	Open an Oncology and Infectious Disease Center in Malawi at Queen Elizabeth Central Hospital
	On September 25, 2012, GBOIG, in partnership with the Company, signed an agreement with the Government of Malawi to open an outpatient clinic at Queen Elizabeth Central Hospital (in Malawi) for the treatment of cancer and infectious disease.  The duration of the Agreement shall be for 25 years with an optional 10-year renewal to be indicated by the Government of Malawi at least three years prior to the expiration of the term.  The Government of Malawi shall bear the upfront costs for the agreement of $2,500,000.
	Distribution Agreements in Nigeria
	Effective November 9, 2012, we signed an exclusive Distribution Agreement with G-Ex Technologies/St. Maris Pharma and GB Pharma Holdings, LLC for the Federal Republic of Nigeria. Under the terms of the Distribution Agreement, G-Ex Technologies/St. Maris Pharma and GB Pharma Holdings LLC will have exclusive marketing and distribution rights to IRT-103 LDN and IRT-104 LDN cream in Nigeria until the end of the term of the agreement on December 31, 2017. We will be responsible for the manufacture and supply of IRT-103 LDN and IRT-104 LDN cream. As part of the Distribution Agreement, G-Ex Technologies/St. Maris Pharma will provide us with a revolving letter of credit for the minimum purchase of 750,000 doses monthly of IRT-103 LDN or IRT-104 LDN cream priced at $1.00 per dose.   There are no upfront fees.
	The Distribution Agreement calls for G-Ex Technologies/St. Maris Pharma and GB Pharma Holdings, LLC to purchase a minimum of 15,000,000 doses monthly within 24 months to maintain the exclusivity of the agreement. Once G-Ex Technologies/St. Maris Pharma and GB Pharma Holdings, LLC reach sales of 1,000,000 doses per day, we have agreed to joint venture a factory in the Federal Republic of Nigeria to meet local demands.
	G-Ex Technologies/St. Maris Pharma is a consortium of companies organized under the laws of the Republic of Nigeria operated by management, a consultant, general pharmaceutical, clinical pharmacy and marketing executives, each with over 25 years of industry experience and well versed in the changing dynamics of the prescription and over-the-counter drug international marketplace. G-Ex Technologies/St. Maris Pharma has been actively supported by medical practice professionals in business and academia who have been involved in the management of related drug therapies for many years.
	The parties have been unable to perform under the agreement because a certificate of free sale was not obtained by the Company until November of 2013, and no extension has been granted.
	In October 2013, the Company announced the signing of a Distribution Agreement with AHAR Pharma, a Nigerian company, to market Lodonal™, in Nigeria for the treatment of autoimmune diseases and cancer.  AHAR intends to distribute Lodonal™ through a local distributor network, an Internet client base and directly to hospitals, pharmacists and doctors in Nigeria. The Company expects to implement the agreement in 2015.  Under the agreement, the Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma’s first-year purchase commitment.
	Agreements with Hubei Qianjiang Pharmaceutical Company
	On October 18, 2012, the Company and Hubei Qianjiang Pharmaceutical Co., Ltd. (“Qianjiang Pharmaceutical”), signed a Venture Cooperation Agreement on New Drug Methionine Enkephalin (the “Venture Agreement”) pursuant to which Qianjiang Pharmaceutical acquired an exclusive license for the production of MENK in China.  The Venture Agreement requires that Qianjiang Pharmaceutical conduct drug research and pilot testing for MENK, organize pre-clinical studies, and apply for clinical trials for MENK with the Chinese State Food and Drug Administration. Under the Venture Agreement, Qianjiang Pharmaceutical must open a co-administration account for the development of MENK in China. Qianjiang Pharmaceutical must pay the Company, upon the marketing of MENK products, a half-year amount equaling 6% of its gross sales from MENK of the preceding half year.  The Company may cancel the Venture Agreement if Qianjiang Pharmaceutical does not pay expenses for a period exceeding six months or does not commence clinical trials within 12-months after receiving certain approvals. Qianjiang Pharmaceutical may cancel the Venture Agreement if the Company fails to perform its obligations for a period of six months or the failure to receive approval of clinical trials is due to the Company’s MENK technologies.  The Venture Agreement was amended on February 24, 2013 to expand the clinical trials from pancreatic to both pancreatic and liver cancer and amended on March 6, 2014 to require Qianjiang Pharmaceutical to commence studies and clinical trials in China and place funds in the co-administration account.
	On August 6, 2014, the Company entered into a Supplementary Agreement on New Drug Methionine – Enkephalin Cooperation (the “Amendment”) with Qianjiang Pharmaceutical, amending the Venture Agreement, as amended. The Company and Qianjiang Pharmaceutical executed the Amendment to accelerate clinical trials in both the United States and China, and agreed to immediately initiate three month Good Laboratory Practice (“GLP”) Toxicology Studies (rat and dog) within 30 days of signing the Amendment. The Amendment requires that the GLP Toxicology Studies Trials are conducted in China in accordance with international standards and standards acceptable to the FDA and that the studies include the following:
	Exploratory Toxicology (nGLP)
	· Dose range finding studies
	· Different species and methods of administration
	· Multiple dosing regimens
	· Estimate the response vs. dose given
	Definitive Toxicology (GLP)
	· Performed in collaboration with Calvert Laboratories (USA) and MPI/Medicillon (China)
	· General toxicology studies
	· Different species and methods of administration
	· Immunogenicity study with NHPs
	Special Toxicology Studies (planned)
	Pursuant to the Amendment, Qianjiang Pharmaceutical will make certain funds available from the co-administrative account opened by Qianjiang Pharmaceutical under the Venture Agreement, in accordance with an approved budget and timeline set forth in the Amendment.  A portion of these funds are expected to be used by Cytocom to run PK and Dosing trials for MENK in the United States.  The Amendment requires Cytocom and Qianjiang Pharmaceutical to meet with the China State Food and Drug Administration to determine that PK and Dosing Trials completed in the United States will be acceptable. All developments and trials run by Cytocom in the U.S. or the European Union will be used for requesting registration approval in China.
	In February 2013, the Company signed a Strategic Framework Agreement for Cooperation with Qianjiang Pharmaceutical. Under the agreement, the parties will work together to further the development of new products and conduct research and development on the Company’s licensed patented technology. Specifically, the parties aim to co-invest to develop and market products focusing on HIV, cancer and related autoimmune system therapies, develop co-ventured manufacturing facilities in China, and develop co-ventured distribution of the developed products in China and Africa. The agreement does not have a definitive term, as each new agreement resulting from the cooperation will set forth the material terms, including, but not limited to, fees, duration and termination therein.
	Supervision and Inspection of Manufacturing in Nicaragua
	On April 23, 2013, the Company signed a Contract with ViPharma for the Supervision and Inspection of Manufacturing Processes as part of its negotiations for a contract for the manufacturing of LDN in a tablet, capsule and/or cream. The contract sets out the terms and conditions under which ViPharma will carry out the services of inspecting and supervising the manufacturing and packaging processes of LDN and ensure compliance with the FDA’s Current Good Manufacturing Practice regulations (“cGMP”) and the Company’s specifications. ViPharma will carry out its obligations in whatever Latin American country the Company ultimately decides to manufacture LDN. Under the contract, ViPharma has the exclusive rights to supervise and inspect all manufacturing processes of LDN in Latin America. The initial term of the agreement is ten years commencing in September 2013, with automatic five-year renewal terms provided neither party is in breach. The agreement may be terminated by (i) mutual agreement, (ii) in the event of a breach after a 45 day cure period or (iii) by either party upon provision of written notice at least 90 days before the end of the agreement, provided however that if the Company terminates the contract without cause it will be required to pay ViPharma a $10 million penalty.
	Operating Leases
	At December 31, 2014, the Company was a party to agreements to lease office space in White Plains, New York, and Orlando, Florida.  The White Plains office is no longer in use.  Cash rental expense for the years ended December 31, 2014 and 2013 was $147,236 and $89,390, respectively.
	In February 2014, a claim was filed for breach of contract and unjust enrichment in the Circuit Court for Montgomery County, Maryland, E.J. Krause & Associates, Inc. v. TNI BioTech, Inc., in which the named plaintiff claims that we breached a sub-sublease. The plaintiff is seeking damages in excess of $75,000, along with costs, attorneys’ fees, pre-judgment interest and post-judgment interest.
	Legal Proceedings
	In October 2014, a claim was filed for breach of contract and unjust enrichment in the United States District Court, Middle District of Florida, Orlando Division, QS Pharma, LLC v. TNI BioTech, Inc. n/k/a Immune Therapeutics, Inc., in which the named plaintiff claims that we breached various proposals between the parties. The plaintiff is seeking an amount of damages to be proven at trial and pre-judgment interest.  The company accrued $210,452 for this claim.

12_Related_Party_Transactions

12. Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
12. Related Party Transactions	In 2012, Webfoot, Inc. provided a loan to the Company in the amount of $121,128. Webfoot, Inc. is owned by the son of Noreen Griffin, the Company's Chief Executive Officer. On February 21, 2013, the Company entered into a formal loan agreement to evidence the amount owed by the Company. In the nine months ended September 30, 2014, the Company repaid $40,000 of the loan.  On September 30, 2014, the remaining balance of $71,128 owed under the agreement, together with accrued and unpaid interest totaling $10,212, was converted into 813,404 shares of the Company’s common stock in full and final settlement of the loan.  The loss on conversion was $162,681.
	In 2012, Noreen Griffin made payments totaling $30,000 on the Company's behalf covering the costs of incorporation and merger-related expenses. On February 13, 2013, the Company entered into a formal loan agreement to evidence repayment of the amount owed on December 31, 2012. On September 30, 2014, the full balance of the loan, together with accrued and unpaid interest totaling $2,870, was converted into 328,701 shares of the Company’s common stock in full and final settlement of the loan.  The loss on conversion was $65,740.
	In 2012, Griffin Enterprises, Inc. made payments totaling $46,000 on the Company's behalf covering the cost of incorporation and merger-related expenses. Griffin Enterprises, Inc. is wholly owned by Noreen Griffin. On February 13, 2013, the Company entered into a formal loan agreement to evidence repayment of the amount owed on December 31, 2012. On September 30, 2014, the full balance of the loan, together with accrued and unpaid interest totaling $4,401, was converted into 504,009 shares of the Company’s common stock in full and final settlement of the loan. The loss on conversion was $100,802.
	On January 3, 2013, the Company formalized the terms under which Kelly O’Brien Wilson, the daughter-in-law of the Company's Chief Executive Officer is employed. Ms. Wilson had been working with the Company in 2012 and her three-year employment agreement is effective as of December 1, 2012. The terms of the agreement define her base salary, a grant of a common stock, and health insurance coverage. Ms. Wilson was issued 500,000 shares of common stock of the Company in January 2014. In 2014, the Company paid compensation to Ms. Wilson totaling $157,582.
	In May 2013, the Company entered into the Shan Agreement and obtained exclusive rights to develop and commercialize the intellectual property developed and owned by Professor Shan as described in detail above under “Patent License Agreements.” In August 2014, Professor Shan executed an Assignment under which he transferred to the Company his entire right, title and interest in and to the licensed patents under the Shan Agreement and to CN 201210302259 Application of combination of LDN and MENK to preparation of anti-cancer drug for the consideration of 500,000 shares of our common stock.
	On July 14, 2012, GBOIG, in partnership with the Company, signed a letter of intent agreement to collaborate with the Government of Malawi to assist in expanding the treatment of cancer, HIV/AIDS and other infectious diseases. The Company and GBOIG will work in connection with the government of Malawi to open and operate clinics that provide treatments for HIV/AIDS, cancer and other infectious diseases. The Company shall contribute $1,000 in initial capital to the venture.  The Company shall be allocated 50% of the net income from the venture.  Either party may terminate the venture with 180 days’ notice to the other party prior to the one-year anniversary of the agreement.  After the one-year anniversary, the agreement may only be terminated with 180 days' notice to the other party if the other party has breached the agreement. GBOIG, a subsidiary of GB Energie LLC, is a Washington D.C. based minority woman-owned business managed by Dr. Gloria B. Herndon. Dr. Herndon is a former director of the Company.  Her position as a director ended on September 4, 2014.
	On September 25, 2012, GBOIG, in partnership with the Company, signed an agreement with the Government of Malawi to open an outpatient clinic at Queen Elizabeth Central Hospital (in Malawi) for the treatment of cancer and infectious disease.  The duration of the agreement shall be for 25 years with an optional 10 year renewal to be indicated by the Government of Malawi at least three years prior to the expiration of the term.  The Government of Malawi shall bear the upfront costs for the agreement of not less than $2,500,000.  GBOIG, a subsidiary of GB Energie LLC, is a Washington D.C. based minority woman-owned business managed by Dr. Gloria B. Herndon. Dr. Herndon is a former director of the Company.  Her position as a director ended on September 4, 2014.

2_Summary_of_Significant_Accou1

2. Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Summary Of Significant Accounting Policies Policies
Basis of Presentation	The accompanying consolidated financial statements have been prepared in accordance with United States (U.S.) generally accepted accounting principles (U.S. GAAP) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented.
	The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2014. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.
Use of Estimates	The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.
Cash, Cash Equivalents, and Short-Term Investments	The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.
Concentration of Credit Risk	Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At December 31, 2014, the Company has no uninsured cash balances.
Segment and Geographic Information	Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.
Fair Value of Financial Instruments	In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments” , the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments.  Cash,  accounts payable, payable to officer, patent liability and net liabilities of discontinued operations are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments.   The carrying value of notes payable and notes payable related party also approximate fair value since they bear market rates of interest and other terms.  None of these instruments are held for trading purposes.
Fair Value Measurements	The ASC Topic 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in accordance with U.S. generally accepted accounting principles, and requires certain disclosures about fair value measurements. In general, fair values of financial instruments are based upon quoted market prices, where available. If such quoted market prices are not available, fair value is based upon internally developed models that primarily use, as inputs, observable market-based parameters. Valuation adjustments may be made to ensure that financial instruments are recorded at fair value. These adjustments may include amounts to reflect counterparty credit quality and the customer's creditworthiness, among other things, as well as unobservable parameters. Any such valuation adjustments are applied consistently over time.
Property and Equipment	Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense from continuing operations for the years ended December 31, 2014 and December 31, 2013 was $2,485 and $1,175, respectively.
Intangible Assets	Costs incurred to acquire and/or develop the Company’s product licenses and patents are capitalized and amortized by straight-line methods over estimated useful lives of seven to sixteen years. Intangible assets are stated at the lower of cost or estimated fair market value.  During the years ended December 31, 2014 and December 31, 2013, the Company capitalized $57,340 and $2,710,539 respectively, of such costs incurred for the Company’s acquisition of licenses for the patents. (See Note 10).  Amortization expense for the years ended December 31, 2014 and December 31, 2013 was $2,876,826 and $2,852,261, respectively.
Impairment of Long-Lived Assets	The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “Property, Plant and Equipment.” If the carrying amount of the asset, including any intangible assets associated with that asset, exceeds its estimated undiscounted net cash flow, before interest, the Company will recognize an impairment loss equal to the difference between its carrying amount and its estimated fair value. In 2014, the Company determined that the carrying amount recoded for the acquisition of licenses and patents related to MENK were impaired, and recorded an impairment loss of $9,908,477. No impairment losses were recognized for the year ended December 31, 2013.
Research and Development Costs	Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.
Income Taxes	The Company follows FASB ASC Topic 740, “Income Taxes” , which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
	The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of December 31, 2014, and 2013, the Company does not have a liability for unrecognized tax uncertainties.
	The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of December 31, 2014, and 2013, the Company has not accrued any interest or penalties related to uncertain tax positions.
Share-Based Compensation and Issuance of Stock for Non-Cash Consideration	The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair market value of the Company’s common stock at the date of the agreement.
	The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “Equity-Based Payments to Non-Employees.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.
Non-controlling Interest	In accordance with ASC 810, Consolidation, the Company consolidates Cytocom, Inc. The non-controlling interests in Cytocom represent the interests of outside shareholders in the equity and results of operations of Cytocom.
	The Company has adopted changes issued by the Financial Accounting Standards Board (“FASB”) to the accounting for non-controlling interests in consolidated financial statements. These changes require, among other items, that a non-controlling interest be included within equity separate from the parent’s equity; consolidated net income be reported at amounts inclusive of both the parent’s and non-controlling interest’s shares; and, separately, the amounts of consolidated net income attributable to the parent and non-controlling interest all be reported on the consolidated statements of operations and comprehensive loss.
Net Loss per Share	Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.
	Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common equivalent shares):
		Year Ended December 31,
		2014		2013
	Common Stock Purchase Warrants		9,296,750		7,957,500
Recent Accounting Standards	During the year ended December 31, 2014 and through March 31, 2015, there were several new accounting pronouncements issued by the Financial Accounting Standards Board.  Each of these pronouncements, as applicable, has been or will be adopted by the Company.  Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.
	The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2014, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

2_Summary_of_Significant_Accou2

2. Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Summary Of Significant Accounting Policies Tables
Schedule of net loss per share		Year Ended December 31,
		2014		2013
	Common Stock Purchase Warrants		9,296,750		7,957,500

3_Property_and_Equipment_Table

3. Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property And Equipment Tables
Schedule of property and equipment		December 31,
		2014			2013
	Property and equipment:
	Computer equipment	$	8,013		$	6,900
	Less accumulated depreciation		(3,778	)		(1,293	)
	Property and equipment, net	$	4,235		$	5,607

4_Accrued_Liabilities_Tables

4. Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities Tables
Schedule of accrued liabilities		December 31,
		2014		2013
	Retainer for legal services	$	60,000	$	-
	Accrued payroll to officers and others		762,633		548,291
	Accrued interest - notes payable		1,808		39,980
	Estimated legal settlement		278,681		-
	Other accrued liabilities		6,933		-
	State payroll taxes		1,784		-
	Total accrued expenses and other liabilities	$	1,111,839	$	588,271

6_Capital_StructureCommon_Stoc1

6. Capital Structure-Common Stock and Common Stock Purchase Warrants (Tables)	12 Months Ended
	Dec. 31, 2014
Capital Structure-common Stock And Common Stock Purchase Warrants Tables
Schedule of outstanding stock warrants		Number of Shares		Exercise Price		Weighted Average Price
	Warrants as of December 31, 2013		7,957,500	$	1.00 – 15.00	$	1.77
	Issued in 2014		2,358,000	$	0.14-1.50	$	1.08
	Expired		-	$	-	$	-
	Exercised		-918,750	$	0.5	$	0.5
	Warrants as of December 31, 2014		9,396,750	$	0.14-15	$	1.72
Summary of outstanding warrants	Expiration Date	Number of Shares		Exercise Price		Remaining Life (years)
	Third Quarter 2015		407,500	$	1.50-2.00		0.75
	Fourth Quarter 2015		268,750	$	1.5		1
	Second Quarter 2016		37,500	$	3.00-5.00		1.5
	Third Quarter 2016		525,000	$	0.50-5.00		1.75
	Third Quarter 2017		1,500.00	$	1.00-1.50		2.75
	Fourth Quarter 2017		2,941,666	$	1.00-9.00		3
	First Quarter 2018		127,500	$	15		3.25
	Second Quarter 2018		33,334	$	15		3.5
	Third Quarter 2018		400,000	$	1.00-1.50		3.75
	Fourth Quarter 2018		1,197,500	$	1.00-1.50		4
	First Quarter 2019		1,048,000	$	1.5		4.25
	Third Quarter 2019		500,000	$	0.5		4.75
	Fourth Quarter 2019		410,000	$	0.14-1.50		5

8_Income_Taxes_Results_of_Oper1

8. Income Taxes - Results of Operations (Tables)	12 Months Ended
	Dec. 31, 2014
Income Taxes - Results Of Operations Tables
Schedule of deferred tax assets		2014			2013
	Net operating losses	$	47,992,000		$	35,160,000
	Stock based compensation		29,020,000			29,019,000
	Amortization and depreciation		1,950,000			970,000
	Capitalization of start-up costs for tax purposes		254,000			1,854,000
	Loss on debt conversion  of debt		4,395,000			2,938,000
	Total deferred tax assets		86,915,000			69,941,000
	Valuation allowance		(86,915,000)			(69,941,000	)
	Total deferred tax assets, net	$	-		$	-
Schedule of income taxes		2014						2013
		Amount			Percent			Amount			Percent
	Benefits for income tax at federal statutory rate	$	16,978,000			34%		$	36,060,000			34	%
	Change in valuation allowance		(16,973,000	)		-34%		$	(36,056,000	)		(34	)
	Permanent differences		(5,000	)		-			(4,000	)		-
	Non-deductible impairment of goodwill		-			-			-			-
		$	-			-		$	-			-	%

1_Organization_and_Description1

1. Organization and Description of Business (Detials Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Organization And Description Of Business Detials Narrative
Net loss from operations	($49,938,213)	($106,060,062)
Cash and cash equivalents	191,987	406,596
Stockholders equity	$2,352,432	$16,631,247	$17,343,837

2_Summary_of_Significant_Accou3

2. Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies Tables
Common Stock Purchase Warrants	9,296,750	7,957,500

2_Summary_of_Significant_Accou4

2. Summary of Significant Accounting Policies (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies Details Narrative
Cash accounts insured Federal Deposit Insurance Corporation	$250,000
Depreciation expense from continuing operations	2,485	1,175
Intangible Assets cost capitalized and amortized	57,340	2,710,539
Amortization expense	$2,876,826	$2,852,261

3_Property_and_Equipment_Detai

3. Property and Equipment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property And Equipment Details
Computer Equipment	$8,013	$6,900
Less accumulated depreciation	-3,778	-1,293
Property and equipment, net	$4,235	$5,607

4_Accrued_Liabilities_Details

4. Accrued Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accrued Liabilities Details
Retainer for legal services	$60,000
Accrued payroll to officers and others	762,633	548,291
Accrued Interest - Notes Payable	1,808	39,980
Estimated legal settlement	278,681
Other accrued liabilities	6,933
State payroll taxes	1,784
Total accrued expenses and other liabilities	$1,111,839	$588,271

5_Notes_Payable_Details_Narrat

5. Notes Payable (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Debt Disclosure [Abstract]
Outstanding promissory notes	$186,067	$817,197
Accrued unpaid interest	1,808
Issuance of common stock for loan expenses and interest	670,000	387,500
Issuance of common stock for loan expenses and interest, amount	$302,450	$6,553,377
Promissiory note interest rate	2.00%
Outstanding promissory note	7,000	0
Notes Payable maturity date	10/17/15

6_Capital_StructureCommon_Stoc2

6. Capital Structure-Common Stock and Common Stock Purchase Warrants (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Number of Warrants
Beginning Balance	7,957,500
Issued	2,358,000
Expired
Exercised	-918,750
Ending Balance	9,396,750
Warrants Price Per Share
Beginning Balance	1.00 B 15.00
Issued	0.14-1.50
Expired
Exercised	0.5
Ending Balance	0.14-15
Weighted Average Exercise Price
Beginning Balance	$1.77
Issued	$1.08
Expired
Exercised	0.5
Ending Balance	$1.72

6_Capital_StructureCommon_Stoc3

6. Capital Structure-Common Stock and Common Stock Purchase Warrants (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Number of Shares	9,396,750	7,957,500
Third Quarter 2015
Number of Shares	407,500
Exercise Price Lower Limit	$1.50
Exercise Price Upper Limit	$2
Remaining Life (years)	9 months
Fourth Quarter 2015
Number of Shares	268,750
Exercise Price Upper Limit	$1.50
Remaining Life (years)	1 year
Second Quarter 2016
Number of Shares	37,500
Exercise Price Lower Limit	$3
Exercise Price Upper Limit	$5
Remaining Life (years)	1 year 6 months
Third Quarter 2016
Number of Shares	525,000
Exercise Price Lower Limit	$0.50
Exercise Price Upper Limit	$5
Remaining Life (years)	1 year 9 months
Third Quarter 2017
Number of Shares	1,500,000
Exercise Price Lower Limit	$1
Exercise Price Upper Limit	$1.50
Remaining Life (years)	2 years 9 months
Fourth Quarter 2017
Number of Shares	2,941,666
Exercise Price Lower Limit	$1
Exercise Price Upper Limit	$9
Remaining Life (years)	3 years
First Quarter 2018
Number of Shares	127,500
Exercise Price Upper Limit	$15
Remaining Life (years)	3 years 3 months
Second Quarter 2018
Number of Shares	33,334
Exercise Price Upper Limit	$15
Remaining Life (years)	3 years 6 months
Third Quarter 2018
Number of Shares	400,000
Exercise Price Lower Limit	$1
Exercise Price Upper Limit	$1.50
Remaining Life (years)	3 years 9 months
Fourth Quarter 2018
Number of Shares	1,197,500
Exercise Price Lower Limit	$1
Exercise Price Upper Limit	$1.50
Remaining Life (years)	4 years
First Quarter 2019
Number of Shares	1,048,000
Exercise Price Upper Limit	$1.50
Remaining Life (years)	4 years 3 months
Third Quarter 2019
Number of Shares	500,000
Exercise Price Upper Limit	$0.50
Remaining Life (years)	4 years 9 months
Fourth Quarter 2019
Number of Shares	410,000
Exercise Price Lower Limit	$0.14
Exercise Price Upper Limit	$1.50
Remaining Life (years)	5 years

6_Capital_StructureCommon_Stoc4

6. Capital Structure-Common Stock and Common Stock Purchase Warrants (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Capital Structure-common Stock And Common Stock Purchase Warrants Details Narrative
Common Stock, Par Value	$0.00	$0.00
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares Outstanding	134,417,210	74,161,639
Weighted average exercise price	$0.69
Discount rate	90.00%
Expected life	5 years
Volatility rate	163.00%
Fair value of stock warrant	$1,748,576	$10,531,073
Warrants issued	2,358,000
Exercisable price, Minimum	$0.14
Exercisable price, Maximum	$1.50
Warrants expire	Warrants expire between January 2016 and December 2019

7_Stock_Compensation_Details_N

7. Stock Compensation (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Issuance of common stock for services	17,178,294	20,903,000
Amortization of stock issued for prepaid services	$22,891,924	$74,798,662
Minimum
Consulting fees amortized period	12 months
Maximum
Consulting fees amortized period	24 months

8_Income_Taxes_Results_of_Oper2

8. Income Taxes - Results of Operations (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Taxes - Results Of Operations Details
Net operating losses	$47,992,000	$35,160,000
Stock based compensation	29,020,000	29,019,000
Amortization and depreciation	1,950,000	970,000
Capitalization of start-up costs for tax purposes	254,000	1,854,000
Loss on debt converrsion of debt	4,395,000	2,938,000
Total deferred tax assets	86,915,000	69,941,000
Valuation allowance	-86,915,000	-69,941,000
Total deferred tax assets

8_Income_Taxes_Results_of_Oper3

8. Income Taxes - Results of Operations (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes - Results Of Operations Details 1
Benefits for income tax at federal statutory rate	$16,978,000	$36,060,000
Change in valuation allowance	-16,973,000	-36,056,000
Permanent differences	-5,000	-4,000
Non-deductible impairment of goodwill	0	0
NOL	$0	$0
Benefits for income tax at federal statutory rate, percent	34.00%	34.00%
Change in valuation allowance, percent	-34.00%	-34.00%
Permanent differences, percent	0.00%	0.00%
Non-deductible impairment of goodwill, percent	0.00%	0.00%
NOL, percent	0.00%	0.00%

10_Lincenses_and_Supply_Agreem1

10. Lincenses and Supply Agreements (Details Narrative) (USD $)	Dec. 31, 2013
Notes to Financial Statements
Patent liability	$118,333
Cost of the patent	$1,372,000

11_Commitments_and_Contingenci1

11. Commitments and Contingencies (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Cash rental expense	$147,236	$89,390